المؤلفون: Ollila-Raj, H, Murumagi, A, Pellinen, T, Arjama, M, Sutinen, E, Volmonen, K, Haikala, HM, Kallioniemi, O, Mayranpaa, MI, Ilonen, I

المصدر: Lung cancer (Amsterdam, Netherlands). 178:213-219

مصطلحات موضوعية: Medicin och hälsovetenskap

URL الوصول: http://kipublications.ki.se/Default.aspx?queryparsed=id:152211955

المؤلفون: Wang Z; Department of Biochemistry and Developmental Biology, University of Helsinki, Helsinki FIN-00014, Finland., Himanen SV; Department of Gene Technology, KTH Royal Institute of Technology, Science for Life Laboratory, Stockholm, Sweden., Haikala HM; Translational Immunology Research Program (TRIMM), Research Programs Unit, Faculty of Medicine, University of Helsinki, Helsinki FIN-00014, Finland.; iCAN Digital Precision Cancer Medicine Flagship, University of Helsinki, Helsinki FIN-00014, Finland., Friedel CC; Institute of Informatics, Ludwig-Maximilians-Universität München, 80333 Munich, Germany., Vihervaara A; Department of Gene Technology, KTH Royal Institute of Technology, Science for Life Laboratory, Stockholm, Sweden., Barborič M; Department of Biochemistry and Developmental Biology, University of Helsinki, Helsinki FIN-00014, Finland.

المصدر: Nucleic acids research [Nucleic Acids Res] 2023 Nov 10; Vol. 51 (20), pp. 10970-10991.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Oxford University Press Country of Publication: England NLM ID: 0411011 Publication Model: Print Cited Medium: Internet ISSN: 1362-4962 (Electronic) Linking ISSN: 03051048 NLM ISO Abbreviation: Nucleic Acids Res Subsets: MEDLINE

مواضيع طبية MeSH: Positive Transcriptional Elongation Factor B*/genetics , Positive Transcriptional Elongation Factor B*/metabolism , RNA Polymerase II*/genetics , RNA Polymerase II*/metabolism, Neoplasms/genetics ; NF-kappa B/genetics ; NF-kappa B/metabolism ; Ribonucleoproteins, Small Nuclear/genetics ; RNA-Binding Proteins/metabolism ; Tumor Suppressor Protein p53/genetics ; Humans ; Cell Line, Tumor

المؤلفون: Son J; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Jang J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Beyett TS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Eum Y; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Haikala HM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Verano A; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Lin M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Hatcher JM; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Kwiatkowski NP; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Eser PÖ; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Poitras MJ; Experimental Therapeutics Core, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Wang S; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Xu M; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Gokhale PC; Experimental Therapeutics Core, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Cameron MD; Department of Molecular Medicine, The Scripps Research Institute, Jupiter, Florida., Eck MJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts., Gray NS; Chemical and Systems Biology, Chem-H, Stanford Cancer Institute, Stanford Medicine, Stanford University, Stanford, California., Jänne PA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

المصدر: Cancer research [Cancer Res] 2022 Apr 15; Vol. 82 (8), pp. 1633-1645.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/therapeutic use , Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Lung Neoplasms*/chemically induced , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics, Exons ; Humans ; Mutation ; Protein Kinase Inhibitors/adverse effects ; Receptor, ErbB-2/metabolism

المؤلفون: Ricciuti B; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Son J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Okoro JJ; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Mira A; Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy., Patrucco E; Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy., Eum Y; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Wang X; Harvard Graduate School of Arts and Sciences, Harvard University, Cambridge, Massachusetts.; Department of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts., Paranal R; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Wang H; School of Life Sciences and Technology, Tongji University, Shanghai, China., Lin M; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Haikala HM; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Li J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Xu Y; School of Life Sciences and Technology, Tongji University, Shanghai, China., Alessi JV; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Chhoeu C; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Redig AJ; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Köhler J; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Dholakia KH; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Chen Y; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Richard E; Institut Bergonié, INSERM U1218, ACTION Laboratory, Bordeaux, France., Nokin MJ; University of Bordeaux, INSERM U1218, ACTION Laboratory, IECB, Pessac, France., Santamaria D; University of Bordeaux, INSERM U1218, ACTION Laboratory, IECB, Pessac, France., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Awad MM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts., Jänne PA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts., Ambrogio C; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.; Department of Molecular Biotechnology and Health Sciences, Molecular Biotechnology Center, University of Torino, Torino, Italy.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Apr 14; Vol. 28 (8), pp. 1640-1650.

نوع المنشور: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Carcinoma, Non-Small-Cell Lung*/genetics , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics , Lung Neoplasms*/pathology, Humans ; Kelch-Like ECH-Associated Protein 1/genetics ; Mitogen-Activated Protein Kinase Kinases/genetics ; Mutation ; NF-E2-Related Factor 2/genetics ; Protein Isoforms/genetics ; Proto-Oncogene Proteins p21(ras)/genetics

المؤلفون: To C; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Beyett TS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Jang J; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; College of Pharmacy, Korea University, Sejong, Korea., Feng WW; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Bahcall M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Haikala HM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Shin BH; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Heppner DE; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.; Department of Chemistry, University at Buffalo, Buffalo, NY, USA., Rana JK; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Leeper BA; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Soroko KM; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Poitras MJ; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Gokhale PC; Experimental Therapeutics Core and Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA, USA., Kobayashi Y; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Division of Molecular Pathology, National Cancer Center Research Institute, Tokyo, Japan., Wahid K; Institute of Biomedicine, MediCity Research Laboratories, University of Turku, Turku, Finland., Kurppa KJ; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA.; Institute of Biomedicine, MediCity Research Laboratories, University of Turku, Turku, Finland., Gero TW; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA., Cameron MD; Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, FL, USA., Ogino A; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Mushajiang M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Xu C; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Zhang Y; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Medicine, Harvard Medical School, Boston, MA, USA., Scott DA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. DavidA_Scott@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. DavidA_Scott@dfci.harvard.edu., Eck MJ; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. michael_eck@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. michael_eck@dfci.harvard.edu., Gray NS; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA. nathanael_gray@dfci.harvard.edu.; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA. nathanael_gray@dfci.harvard.edu.; Department of Medicinal Chemistry and Department of Chemistry and Systems Biology, Stanford University, Stanford, CA, USA. nathanael_gray@dfci.harvard.edu., Jänne PA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. pasi_janne@dfci.harvard.edu.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. pasi_janne@dfci.harvard.edu.; Department of Medicine, Harvard Medical School, Boston, MA, USA. pasi_janne@dfci.harvard.edu.

المصدر: Nature cancer [Nat Cancer] 2022 Apr; Vol. 3 (4), pp. 402-417. Date of Electronic Publication: 2022 Apr 14.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.

بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101761119 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2662-1347 (Electronic) Linking ISSN: 26621347 NLM ISO Abbreviation: Nat Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Carcinoma, Non-Small-Cell Lung*/drug therapy , Lung Neoplasms*/drug therapy, Adenosine Triphosphate/therapeutic use ; ErbB Receptors/genetics ; Humans ; Mutation ; Protein Kinase Inhibitors/pharmacology

المؤلفون: Al-Akhrass H; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Finland., Pietilä M; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Finland., Lilja J; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Finland., Vesilahti EM; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Finland., Anttila JM; Finnish Cancer Institute, FICAN South Helsinki University Hospital & Medical Faculty, University of Helsinki, Finland., Haikala HM; Finnish Cancer Institute, FICAN South Helsinki University Hospital & Medical Faculty, University of Helsinki, Finland., Munne PM; Finnish Cancer Institute, FICAN South Helsinki University Hospital & Medical Faculty, University of Helsinki, Finland., Klefström J; Finnish Cancer Institute, FICAN South Helsinki University Hospital & Medical Faculty, University of Helsinki, Finland., Peuhu E; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Finland.; Institute of Biomedicine, Cancer Research Laboratory FICAN West, University of Turku, Finland., Ivaska J; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Finland.; Department of Life Technologies, University of Turku, Finland.; InFLAMES Research Flagship Center, University of Turku, Finland.

المصدر: Molecular oncology [Mol Oncol] 2022 Jan; Vol. 16 (1), pp. 116-129. Date of Electronic Publication: 2021 Oct 10.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/pharmacology , Antineoplastic Agents*/therapeutic use , Breast Neoplasms*/pathology, Adaptor Proteins, Vesicular Transport ; Animals ; Antibodies, Monoclonal/pharmacology ; Cell Line, Tumor ; Drug Resistance, Neoplasm ; Female ; Humans ; Mice ; Receptor, ErbB-2/metabolism ; Receptor, ErbB-3 ; Trastuzumab/pharmacology

المؤلفون: Haikala HM; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Lopez T; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Köhler J; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Eser PO; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Xu M; Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Zeng Q; Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Teceno TJ; Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Ngo K; Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Zhao Y; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Ivanova EV; Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Bertram AA; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Leeper BA; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, Massachusetts., Chambers ES; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Adeni AE; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Taus LJ; Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Kuraguchi M; Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Kirschmeier PT; Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Yu C; Global Oncology R&D, Daiichi Sankyo, Basking Ridge, New Jersey., Shiose Y; DS Oncology Function Biomarker and Translational Research Department, Daiichi Sankyo, Shinagawa R&D Center, Tokyo, Japan., Kamai Y; Oncology Research Laboratories I, Daiichi Sankyo Co., Ltd., Qiu Y; Global Oncology R&D, Daiichi Sankyo, Basking Ridge, New Jersey., Paweletz CP; Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Gokhale PC; Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.; Experimental Therapeutics Core, Dana-Farber Cancer Institute, Boston, Massachusetts., Jänne PA; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. pasi_janne@dfci.harvard.edu.; Harvard Medical School, Boston, Massachusetts.; Robert and Renee Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts.

المصدر: Cancer research [Cancer Res] 2022 Jan 01; Vol. 82 (1), pp. 130-141. Date of Electronic Publication: 2021 Sep 21.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*therapeutic use , ErbB Receptors/*antagonists & inhibitors , Immunoconjugates/*metabolism , Receptor, ErbB-3/*metabolism, Animals ; Antineoplastic Agents/pharmacology ; Apoptosis ; Cell Culture Techniques ; Cell Line, Tumor ; Humans ; Mice

المؤلفون: Eser PÖ; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA.; Harvard Medical School, Boston, MA 02115, USA., Paranal RM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Son J; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., Ivanova E; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Kuang Y; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Haikala HM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., To C; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., Okoro JJ; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Dholakia KH; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Choi J; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Eum Y; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Ogino A; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., Missios P; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA., Ercan D; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Xu M; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Poitras MJ; Experimental Therapeutics Core, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Wang S; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Ngo K; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Dills M; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Yanagita M; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Lopez T; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Lin M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Tsai J; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Floch N; Oncology R&D, Bioscience, AstraZeneca, CRUK Cambridge Institute, Robinson Way, Cambridge CB2 0RE, UK., Chambers ES; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Heng J; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Anjum R; Bioscience, Oncology R&D, AstraZeneca, 25 Gatehouse Park, Waltham, MA 02451, USA., Santucci AD; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Michael K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Schuller AG; Bioscience, Oncology R&D, AstraZeneca, 25 Gatehouse Park, Waltham, MA 02451, USA., Cross D; Global Medical Affairs, Oncology Business Unit, AstraZeneca, 136 Hills Road, Cambridge CB2 8PA, UK., Smith PD; Oncology R&D, Bioscience, AstraZeneca, CRUK Cambridge Institute, Robinson Way, Cambridge CB2 0RE, UK., Oxnard GR; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., Barbie DA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Sholl LM; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., Bahcall M; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA., Palakurthi S; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Gokhale PC; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Experimental Therapeutics Core, Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Paweletz CP; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Daley GQ; Harvard Medical School, Boston, MA 02115, USA.; Stem Cell Program, Boston Children's Hospital, Boston, MA 02115, USA.; Harvard Stem Cell Institute, Cambridge, MA 02138, USA., Jänne PA; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.; Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02215, USA.; Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, MA 02215, USA.

المصدر: Science translational medicine [Sci Transl Med] 2021 Sep; Vol. 13 (609), pp. eabb3738. Date of Electronic Publication: 2021 Sep 01.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE

مواضيع طبية MeSH: ErbB Receptors*/genetics , Lung Neoplasms*/drug therapy , Lung Neoplasms*/genetics, Cell Line, Tumor ; Drug Resistance, Neoplasm/genetics ; Humans ; Mutation/genetics ; Protein Kinase Inhibitors/pharmacology ; Protein Kinase Inhibitors/therapeutic use

المؤلفون: Haikala HM; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts., Jänne PA; Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. Pasi_Janne@dfci.harvard.edu.; Harvard Medical School, Boston, Massachusetts.

المصدر: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2021 Jul 01; Vol. 27 (13), pp. 3528-3539. Date of Electronic Publication: 2021 Feb 19.

نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review

بيانات الدورية: Publisher: The Association Country of Publication: United States NLM ID: 9502500 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Drug Resistance, Neoplasm*/genetics , Receptor, ErbB-3*/genetics, Cell Line, Tumor ; ErbB Receptors/genetics ; Humans

المؤلفون: Qiao X; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.; Institute of Biomedicine, University of Turku, Turku, Finland.; TuDMM Doctoral Programme, University of Turku, Turku, Finland., Liu Y; Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland.; Institute of Biotechnology, University of Helsinki, Helsinki, Finland., Prada ML; Theodor Boveri Institute and Comprehensive Cancer Center, Mainfranken, Biocenter, University of Würzburg, Würzburg, Germany., Mohan AK; Faculty of Science and Engineering, Cell Biology, Åbo Akademi University, Turku, Finland., Gupta A; Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland., Jaiswal A; Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland., Sharma M; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.; Institute of Biomedicine, University of Turku, Turku, Finland.; TuDMM Doctoral Programme, University of Turku, Turku, Finland., Merisaari J; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.; Institute of Biomedicine, University of Turku, Turku, Finland.; TuDMM Doctoral Programme, University of Turku, Turku, Finland., Haikala HM; Research Programs Unit/Translational Cancer Medicine & HiLIFE, University of Helsinki, Helsinki, Finland., Talvinen K; Institute of Biomedicine, University of Turku, Turku, Finland., Yetukuri L; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland.; Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland., Pylvänäinen JW; Turku BioImaging, University of Turku and Åbo Akademi University, Turku, Finland., Klefström J; Research Programs Unit/Translational Cancer Medicine & HiLIFE, University of Helsinki, Helsinki, Finland., Kronqvist P; Institute of Biomedicine, University of Turku, Turku, Finland., Meinander A; Faculty of Science and Engineering, Cell Biology, Åbo Akademi University, Turku, Finland., Aittokallio T; Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.; Department of Mathematics and Statistics, University of Turku, Turku, Finland., Hietakangas V; Faculty of Biological and Environmental Sciences, University of Helsinki, Helsinki, Finland.; Institute of Biotechnology, University of Helsinki, Helsinki, Finland., Eilers M; Theodor Boveri Institute and Comprehensive Cancer Center, Mainfranken, Biocenter, University of Würzburg, Würzburg, Germany., Westermarck J; Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland. jukka.westermarck@bioscience.fi.; Institute of Biomedicine, University of Turku, Turku, Finland.

المصدر: Cancer research [Cancer Res] 2020 Apr 01; Vol. 80 (7), pp. 1414-1427. Date of Electronic Publication: 2020 Feb 06.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE

مواضيع طبية MeSH: Breast Neoplasms/*genetics , DNA-Binding Proteins/*genetics , Drosophila Proteins/*genetics , Proto-Oncogene Proteins c-myc/*genetics , Transcription Factors/*genetics , Ubiquitin-Protein Ligases/*genetics, Animals ; Animals, Genetically Modified ; Apoptosis/genetics ; Breast/pathology ; Breast Neoplasms/mortality ; Breast Neoplasms/pathology ; Cell Line, Tumor ; DNA-Binding Proteins/metabolism ; Drosophila Proteins/metabolism ; Female ; Gene Amplification ; Gene Expression Regulation, Neoplastic ; Humans ; Kaplan-Meier Estimate ; Models, Animal ; Protein Stability ; Proto-Oncogene Proteins c-myc/metabolism ; RNA-Seq ; Tissue Array Analysis ; Transcription Factors/metabolism ; Ubiquitin-Protein Ligases/metabolism ; Ubiquitination/genetics